Literature DB >> 12087575

Genetic factors play an important role in the pathogenesis of hyperlipidemia post-transplantation.

Carlos A Aguilar-Salinas1, Araceli Díaz-Polanco, Eduardo Quintana, Nayeli Macias, Adriana Arellano, Erika Ramírez, María Luisa Ordóñez, Consuelo Velásquez-Alva, Francisco J Gómez Pérez, Josefina Alberú, Ricardo Correa-Rotter.   

Abstract

BACKGROUND: Our purpose was to identify factors associated with hyperlipidemia post-transplantation in a Hispanic population.
METHODS: From 1985 to 1999, a kidney graft survival longer than 3 months occurred in 293 cases at the Instituto Nacional de la Nutrición. Most of the patients living in Mexico City were included (n = 83). The evaluation included a questionnaire, blood samples, and assessment of body composition and dietary habits. As many as possible first-degree relatives were studied.
RESULTS: Women had higher values of cholesterol (236 +/- 51 versus 215 +/-41; P < 0.05), low-density lipoprotein cholesterol (147 +/- 42 versus 131 +/- 34; P = 0.05), high-density lipoprotein cholesterol (57.3 +/- 14 versus 47.9 +/- 14; P = 0.002) and high-density lipoprotein-2 cholesterol. Isolated hypercholesterolemia was the most common lipid abnormality (40.9%), followed by mixed hyperlipidemia. Lipoprotein (a) greater than 30 mg/dL was found in 13 cases. Familial combined hyperlipidemia (FCHL) in the patient's relatives was a marker for dyslipidemia (odds ratio, 7.04; 95% confidence interval, 1.2 to 59.7). These cases had a worse lipid profile. Cyclosporine-treated FCHL patients had higher lipid levels compared with the non-FCHL, cyclosporine-treated patients. The effects of cyclosporine on the lipid levels were lower, but significant, after the exclusion of the FCHL cases.
CONCLUSION: Post-transplant dyslipidemia is determined by genetic and environmental factors. FCHL in the patient's relatives was associated with post-transplant hyperlipidemia; an additive effect with cyclosporine was found. The evaluation of the lipid profile of relatives may be useful for the assessment of the risk of post-transplant dyslipidemia. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12087575     DOI: 10.1053/ajkd.2002.33926

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  3 in total

1.  Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders.

Authors:  Silvestre García-de-la-Puente; José Luis Arredondo-García; Pedro Gutiérrez-Castrellón; Aurora Bojorquez-Ochoa; Edith Reyna Maya; María Del Pilar Pérez-Martínez
Journal:  Pediatr Nephrol       Date:  2009-02-24       Impact factor: 3.714

2.  Influence of diet on atherogenic risk in children with renal transplants.

Authors:  Luis Aldámiz-Echevarría; Alfredo Vallo; Pablo Sanjurjo; Javier Elorz; José Angel Prieto; José Ignacio Ruiz; Juan Rodríguez-Soriano
Journal:  Pediatr Nephrol       Date:  2004-07-16       Impact factor: 3.714

Review 3.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.